Though unfortunate, pandemic has demonstrated the prophylactic value of nucleic acid in modern health care, especially with the warp speed development of mRNA-based COVID vaccine. Coincidentally, we also witnessed the rapid advance of RNAi therapeutic from concept to regulatory approval in about the same time. The industry is exhilarating about the future of oligonucleotide-based therapeutic starting from ultra-rare diseases and shifting towards prevalent diseases. Having witnessed many startup biotech companies enthusiastically established to address these unsolved issues and unmet needs while struggled to secure resources in manufacturing these products in a timely manner due to the lack of global production capacity and the scarcity of talent in oligonucleotide, the founders of Synoligo Biotechnologies felt the call to action. The company was founded as a contract research organization and specializes in manufacturing complicated, highly modified oligonucleotide.